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Abstract Significant progress in research has been made in
the areas of sex-specific aspects of cardiovascular disease.
Despite these advances, coronary artery disease (CAD) is the
leading cause of death of women in the Western world. Over
the past decade, the focused research on women at risk for
ischemic heart disease has helped to clarify our understanding
of some of the sex-specific factors, which are important in
detecting CAD. In women, the detection and evaluation of
physiologically significant CAD is challenging, especially
given that traditional tests designed to detect focal areas of
coronary artery stenosis are less sensitive and specific in
female patients who have a lower prevalence of obstructive
coronary disease, greater burden of symptoms, and a high
atherosclerotic burden. In this article, we review the available
evidence on the role of contemporary cardiovascular imaging
techniques in evaluating ischemic heart disease in women.
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Introduction
Within the past two decades, significant progress in the
identification and treatment of risk factors for coronary
artery disease (CAD) as well as advances in diagnosis and
treatment of ischemic heart disease (IHD) have resulted in a
decline in mortality in the United States [1]. The recent
National Health Statistics and Center for Disease Control
data show a reduction in coronary heart disease (CHD) age-
adjusted death rates for women by 26.9% since 1999 [1].
This decline in coronary deaths may be credited in part to a
combination of reduction and treatment of major coronary
risk factors as well as the application of evidence-based
treatments for established CAD [2, 3]. Despite this dramatic
improvement, CHD remains the leading cause of death of
US women, claiming the lives of over 210,000 in 2005 [4].
Therefore, early identification of women at risk for CAD is
crucial, especially given that sudden cardiac death is often
the first manifestation of CAD in a high proportion of
women (52%), compared with men (42%) [5].
The focus on sex-specific cardiovascular disease research
has resulted in the development of a robust, multifactorial
evidence base for the role of an assortment of diagnostic tests
inwomenwith suspected myocardial ischemia[6, 7]. Notable
findings relevant to the practicing clinician include 1) the
shift in focus from diagnostic accuracy in detecting CAD to
risk assessment as a means to guiding therapy in women
with symptoms suggestive of IHD; and 2) the observed
paradoxical sex differences in which women with symptoms
suggestive of IHD and documented ischemia on noninvasive
imaging have less anatomic obstructive CAD but yet worse
prognosis compared with age-matched men [6, 8, 9••].
Recently reviewed data demonstrated that symptomatic
women with angiographically normal or nonobstructive
coronary stenoses have increased rates of myocardial
infarction (MI), stroke, hospitalization for congestive heart
failure, and cardiac mortality compared with a similarly
matched cohort of patients without symptoms [10••].
Therefore, the evolving evidence that “at-risk” women may
have a high burden of atherosclerosis as evidenced by diffuse
coronary atherosclerosis more often than focal lesions makes
noninvasive evaluation increasingly challenging [6].
Based on recent insights on the complex pathophysiology
of CHD including the spectrum of obstructive CAD, and
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Shaw et al. [9••] proposed the use of the term ischemic heart
disease as a more appropriate term for the discussion specific
to women, rather than CAD or CHD. Although, the evidence
thus far indicates a high prevalence of obstructive CAD with
flow-limiting stenosis in men and elderly women with acute
coronary syndrome (ACS), in over 50% of women undergo-
ing cardiac catheterization for ACS there is no evidence of
obstructive CAD [9••]. These recent findings pave the way
for an expanded role of cardiac imaging to investigate
other parameters implicated in the spectrum of IHD in
women—the coronary and noncoronary atherosclerotic
burden and methods to detect dysfunction of the
coronary endothelium, reserve, and microvasculature.
We review the literature regarding the noninvasive
assessment of CAD in symptomatic women, with a
specific emphasis on the insights from recent publica-
tions with respect to the noninvasive assessment of IHD
in women.
Role of the Exercise Electrocardiogram: Is It Sufficient
to Assess Risk in Women?
As per the American College of Cardiology/American Heart
Association guidelines, nonimaging treadmill exercise stress
testing continues to be appropriate first-line test in symptom-
atic women with a normal resting 12-lead electrocardiogram
(ECG) who are at intermediate risk for CHD based on risk
factors and symptoms and are capable of maximal exercise
stress [7, 11]. Recent evidence demonstrated the lower
sensitivity and specificity of treadmill exercise testing for
detecting obstructive CAD in women compared with men
[12]. Coupled with the lower prevalence of obstructive CAD
in women and lower exercise tolerance, the use of the
traditional definition of an abnormal treadmill exercise stress
test defined as reversible ST-segment depressions (≥1m m
horizontal or downsloping) leads to frequent underdiagnosis
of obstructive CAD. In a meta-analysis of 3,721 women
evaluated for detecting obstructive CAD with treadmill stress
testing, ST-segment depression (≥1-mm horizontal or down-
sloping changes) during the test was shown to have a
sensitivity and specificity in women of 61% and 70%,
respectively [12]. This finding is compared with men whose
treadmill stress test sensitivity and specificity has been found
to be almost 10% higher [11]. Although several publications
support a higher false-positive rate of exercise ECG in
women compared with men, accuracy for detecting obstruc-
tive CAD is dependent on the morphology, magnitude, and
duration of the ECG changes. Marked ST-segment changes
(ie, ≥2-mm) horizontal or downsloping ST depression at low
workloads and persisting into recovery are all sensitive
markers for the presence of obstructive CAD in women and
men [13]. False-positives are more often seen with exercise-
induced upsloping ST changes in women. Variables felt to
contribute to the false-positive stress-induced ECG changes
noted in women include 1) low QRS voltage and 2) the
digoxin-like effect of estrogen with resultant exercise-
induced ST depression [7].
With regard to prognosis, the exercise ECG provides
important data on risk of cardiac death or MI. The addition
of variables such as functional capacity and calculation of
the Duke treadmill score have been shown to enhance the
prognostic ability of the treadmill ECG test in women [13].
The Duke treadmill score, defined as exercise time—(5×
ST-segment deviation)−4×chest pain [1 = nonlimiting, 2 =
limiting]—can accurately predict cardiac death [13].
Despite the inability of at-risk women to achieve maximum
exercise stress, duration of exercise as manifested in
metabolic equivalents (METs) is by far the strongest
prognostic variable from treadmill exercise stress ECG
[14, 15]. A sex-specific nomogram for predicting normative
values of exercise for women has been devised based on
age [16]. Limited functional capacity (<5 METs) has been
shown to be a consistent marker of worsened prognosis. In
the St. James WTH (Women Take Heart) Project, of the
5,721 asymptomatic women who underwent baseline
symptom-limited stress ECG, those who achieved less than
5 METs had a greater than three times higher death rate
than those who achieved more than 8 METs. At 20-year
follow-up, nearly 20% of women achieving only less than
5.5 METs of exercise had died compared with 8% with
peak METs of 9.3 [16].
For the clinician determining which women are capable
of achieving maximum stress with the exercise ECG, the
use of the Duke Activity Status Index (DASI) can help in
predicting functional capacity. The DASI score, a weighted
scoring system that uses a 12-question survey, has been
validated in women to estimate the METs associated with
the activities of daily living [17]. Using this scale, the
investigators from the WISE (Women’s Ischemia Syndrome
Evaluation) study demonstrated an increased risk of
cardiovascular death and nonfatal MI for women with a
calculated DASI score of less than 5 METs (Table 1)[ 17].
Role of Stress Echocardiography
Stress echocardiography, with exercise or dobutamine phar-
macologic stress, can be used to identify stress-induced
ischemia. By providing information on the presence and
location of wall-motion abnormalities related to a decrease in
regional myocardial blood flow, the extent and location of
ischemia can be defined.
The diagnostic role of stress echocardiography in women
has been well established. Aggregate data analysis of over
148 Curr Cardiol Rep (2010) 12:147–1541,000 women has shown a high accuracy for identifying
physiologically significant CAD, with a mean sensitivity of
81% and a specificity of 86% [7, 18, 19]. In symptomatic
women who are incapable of exercise, dobutamine stress
echocardiography reliably detects multivessel disease, with
reported sensitivities from 75% to 93% and specificities of
79% to 92% [7]. Based on recent studies, stress echocar-
diography with exercise or dobutamine stress is equally
accurate for diagnosing physiologically significant CAD in
women as in men. Stress echocardiography has been shown
to be clinically useful for estimating cardiovascular prog-
nosis in women [18, 20, 21]. In a study evaluating 5-year
survival in 4,234 female patients undergoing exercise stress
echocardiography, survival in patients with no evidence of
ischemia was found to be 99.4%, 97.6% with evidence of
single-vessel ischemia, and 95% in the setting of multiple-
vessel ischemia [21]. Although an abnormal stress echo-
cardiography correlates with a high cardiac event rate in
women, a recent meta-analysis comparing dobutamine
stress echocardiography to exercise single photon emission
computed tomography (SPECT) myocardial perfusion
imaging (MPI) revealed a yearly rate of 0.75% of
cardiovascular death and MI in the setting of a low-risk
dobutamine echocardiography compared with 0.3% per
year in low-risk exercise MPI [22]. The authors concluded
that in the ischemic cascade, perfusion abnormalities
detected by SPECT MPI precede the wall-motion abnor-
malities seen with stress echocardiography. Wall-motion
abnormalities often occur in the setting of advanced
stenosis and with less predictability in areas supplied by
mild-to-moderate coronary artery stenoses. Given the fact
that an acute MI often presents in areas subtended by a less
critical stenosis, stress echocardiography may underesti-
mate risk in women with less advanced CAD. Therefore, in
women, a negative or low-risk stress echocardiography has
a higher cardiac death or MI rate compared with a low-risk
stress MPI [22].
Stress echocardiography in at-risk women has improved
diagnostic and prognostic accuracy over exercise treadmill
testing even when ECG stress interpretation is combined
with the use of exercise capacity and hemodynamic data
[19]. Compared with other noninvasive cardiac imaging
modalities (eg, SPECT, cardiac CT, coronary artery calcium
[CAC]), a specific benefit of stress echocardiography for
evaluating at-risk women is the absence of radiation
exposure.
Role of MPI with SPECT
SPECTwithECG gating, a nuclear-basedtechnique, provides
quantitative information on myocardial perfusion, regional
and global left ventricular function, and end-systolic and end-
diastolic volumes. The diagnostic and prognostic value of
contemporary techniques of SPECT MPI in at-risk women
has beensupportedbya growing bodyofevidence-baseddata
[7, 23, 24]. Traditionally, SPECT MPI has been reported to
have challenges that are specific to women. Technical
limitations in women (including photon attenuation by breast
tissue, lower prevalence of epicardial CAD, and small left
ventricular chamber size) have accounted for past publica-
tions with decreased sensitivity and specificity [23, 25].
Advances in SPECT MPI have led to improvements of the
limitations that are specific to women. Contemporary SPECT
Table 1 Duke activity status index
Can you: Yes No Weight
1 Take care of self (ie, eating dressing, bathing, or using the toilet)? 2.75
2 Walk indoors (eg, around the house)? 1.75
3 Walk a block or two on level ground? 2.75
4 Climb a flight of stairs or walk uphill? 5.50
5 Run a short distance? 8.00
6 Do light work around the house (eg, dusting or washing dishes)? 2.70
7 Do moderate work around the house (eg, vacuuming, sweeping floors or carrying in groceries)? 3.50
8 Do heavy work around the house (eg, scrubbing floors or lifting or moving heavy furniture)? 8.00
9 Do yard work around the house (eg, raking leaves, weeding, or pushing a power mower)? 4.50
10 Have sexual relations? 5.25
11 Participate in moderate recreational activities (eg, golf, bowling, dancing, double tennis or throwing a baseball or
football)?
6.00
12 Participate in strenuous sports (eg, swimming, single tennis, football, basketball, or skiing)? 7.50
Scoring the Duke Activity Status Index (DASI): Add the point values for all questions checked in the Yes column and divide by 3.5 to calculate
the estimated DASI metabolic equivalents
(From Shaw et al. [17]; with permission.)
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artifact protocols, and the use of the higher-energy
radioisotope technetium have resulted in enhanced diagnostic
accuracy for evaluating physiologically significant CAD in
women [7, 26–29].
SPECT MPI with pharmacologic stressisworth discussing
because at-risk women are generally older and often have
decreasedexercisecapacitywhentheypresentwithsymptoms
of IHD [7, 30]. Vasodilator stress has been shown to be
accurate in detecting physiologically significant CAD in
women, with reported sensitivity of 91% and specificity of
86% for detecting a greater than 50% coronary artery
stenosis [30].
A robust body of evidence supports the excellent
prognostic accuracy of exercise and pharmacologic stress
MPI in women. The prognostic value of MPI has been well
established, with the size and severity of defects directly
related to the annual risk of a cardiac event, independent of
sex [24, 31, 32]. Pooled MPI data in over 7,000 women
demonstrate a cardiac event rate of less than 0.7% with a
normal study (and a 5% annual cardiac death rate for
women with moderate-to-severe perfusion abnormalities)
[32]. Vasodilator pharmacologic stress was shown to be
effective in the risk assessment of diabetic women with
suspected and known IHD. In a cohort of 2,656 women and
2,677 men who underwent adenosine SPECT, the annual
CAD mortality rate in the setting of a moderately abnormal
scan was roughly the same for nondiabetic men and
women, 2.7% and 2.8%, respectively. Diabetic women with
normal scans were at increased risk for CAD mortality at
1.6%, compared with diabetic men with a risk of 0.8% and
nondiabetic womenwith a riskof0.8%[33]. Diabetic women
with severely abnormal MPI studies are at highest risk, with
annual CAD mortality rates of 8.5% versus 6.1% in
nondiabetic women. Of note, diabetic women with evidence
of ischemia on MPI were at highest risk for cardiac event if
insulin was used to manage their diabetes [33].
Future Directions in Noninvasive Imaging in Women
The growth in imaging modalities combined with the
ability to define abnormalities specific to the coronary and
vascular tree have provided insight into the pathogenesis of
IHD in women. Clinical trials such as the WISE study have
provided evidence to support the fact that several mecha-
nisms contribute to the worse outcomes and continued
symptoms in the cohort of women who have no evidence of
obstructive CAD. In these women, microvascular dysfunc-
tion of the coronary tree may in part account for the
paradoxical finding of a greater symptom burden and high
cardiac mortality despite the lower burden of obstructive
CAD. Although men and women have a similar amount of
coronary plaque, data from recent trials and intravascular
ultrasound and pathology studies underscore the limitations
of traditional testing algorithms in estimating risk in these
women. Notable findings include 1) a higher prevalence of
“positive” or outward or negative coronary artery remodel-
ing in women compared with men; 2) increased endothelial
dysfunction with inability of the arteries and arterioles to
dilate due to limited production of the vasodilator nitric
oxide by the endothelium; and 3) smaller coronary arteries
per body surface area compared with men, which might
further magnify symptoms due to stenosis or endothelial
dysfunction [34••]. The development of protocols and
attention on methods to detect subclinical atherosclerosis
and endothelial dysfunction promise to reveal a new model
for heart disease in women [34••]. As we shift our focus
from the detection of flow-limiting CAD lesions, cardiac
imaging techniques with cardiac CT, positron emission
tomography (PET), and cardiac magnetic resonance imag-
ing (CMR) will play a future role as imaging is expanded to
include methods to investigate other parameters implicated
in the spectrum of IHD in women—the coronary and
noncoronary atherosclerotic burden including methods to
detect dysfunction of the coronary endothelium, reserve,
and microvasculature.
Role of MPI with PET
MPI with PET provides higher spatial resolution than
SPECT, and is a powerful noninvasive modality for the
diagnosis and risk assessment of CAD [35, 36]. The ability
to calculate absolute blood flow in coronary beds, assess
wall motion at peak hyperemia with vasodilator stress, and
evaluate coronary flow reserve enhances the diagnostic and
prognostic accuracy of PET imaging [36, 37]. The intrinsic
ability of PET to correct for photon attenuation provides
enhanced specificity in evaluating IHD as it corrects for
attenuation artifacts, such as breast tissue artifact and soft
tissue attenuation in obese women [35, 36]. Although there
is a paucity of sex-specific data with PET perfusion
imaging, the identification of physiologically significant
CAD has been shown to be high, with a sensitivity of 90%,
specificity of 89%, and overall diagnostic accuracy of 90%
[35]. Vasodilator stress MPI with PET, using rubidium-82
(Rb-82), offers several advantages for assessing IHD in at-
risk obese women who are not capable of maximum
exercise stress and in whom soft tissue attenuation can
decrease the diagnostic accuracy of SPECT.
Emerging data on sex-specific prognosis support the role
of PET in the risk assessment of women and men with
known or suspected IHD. In a recent study on a cohort of
over 1,400 patients followed up for 1 year, Rb-82 PET MPI
with vasodilator stress was shown to provide incremental
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left ventricular ejection fraction (LVEF) to predict survival
free of cardiac events and all-cause death. The addition of
LVEF reserve was shown to provide significant indepen-
dent and incremental value to Rb-82 MPI for predicting the
risk of future adverse events [38]. Coronary flow reserve, a
marker of endothelial dysfunction, was recently studied
with PET [39]. In a small study of a cohort of 26 women
and 16 men with complaints of chest pain and normal
coronary angiography, PET perfusion with N-13 ammonia
demonstrated reduced coronary flow reserve in women with
symptoms of typical angina and no evidence of obstructive
CAD. This method shows promise for the risk stratification
and management of women with symptoms that may be
due to endothelial dysfunction [40].
Role of CAC Scoring and CT Angiography
Cardiac CT, using electronbeamtomographyormultidetector
CT, allows a noninvasive anatomic quantification of CAC,
noncalcified coronary artery plaque, and degree of coronary
artery stenosis. Although not specific for luminal obstruction,
theCACscoreprovidesanestimateofthetotalatherosclerotic
plaque burden and thereby provides information regarding
cardiac risk. The presence of calcification signifies the
presence of atherosclerosis because calcification does not
occur in a normal vessel wall. Recent data reveal an evolving
role of cardiac CT in the identification and risk assessment of
CAD in at-risk women [41]. Sex-specific data on the role of
CAC in evaluating at-risk symptomatic women demonstrate
a high negative predictive value when correlated with
coronary angiography. In a cohort of 539 symptomatic
women who underwent clinically indicated coronary angi-
ography, 41% had a normal angiogram and no evidence of
CAC, with a negative predictive value of 100%. There was a
greater prevalence of obstructive CAD in women with CAC
scores of more than 100 [41].
CAC detection adds incremental prognostic value to
traditional risk factors in asymptomatic women at risk for
IHD [42, 43]. In an asymptomatic cohort of 4,191 women
and 6,186 men, CAC was associated with a higher risk of
death in women than in men at each level of calcification.
At 5-year follow-up, 80% of women with CAC scores of
greater than 1,000, representing extensive coronary calcifi-
cation, were alive compared with 98.4% of women with no
evidence of CAC [41].
Cardiac CT angiography (CTA) allows the noninvasive
anatomic evaluation of the coronary arteries. The introduction
of updated software and 64-slice multidetector technology
facilitates the noninvasive anatomic assessment of obstructive
CAD with a high diagnostic accuracy with sensitivities and
specificities in the ranges of 80% to 98% and 86% to 98%,
respectively [43]. No sex-specific differences were noted
with contemporary computed tomographic angiography
(CTA) techniques [44]. In a recent study of 52 men and 51
women who were evaluated with 64-multislice CT and
coronary angiography with segmental comparison, sensitiv-
ity and specificity were similar by gender at 85% and 99%,
respectively [44]. Although the exposure to radiation with
CTA remains a concern, the introduction of dual-source
cameras and new protocols using techniques of retrospective
ECG-gating show promise of decreasing the radiation dose
while maintaining excellent image quality [45]. Cardiac CTA
with its ability to facilitate visualization of the coronary
lumen and vessel wall may be a useful noninvasive testing
modality in the diagnosis and risk assessment of symptom-
atic women, in the setting of an abnormal or equivocal
noninvasive stress imaging test.
Role of CMR
MRI is emerging as an important imaging modality for
assessing CAD in women. In addition to the ability to
evaluate anatomic obstruction by angiography and blood
flow assessment, MR perfusion imaging allows functional
assessment of pharmacologic vasodilator-induced ischemia
and segmental wall-motion evaluation. Recent studies have
shown that MRI with its superior spatial and temporal
resolution can identify subendocardial ischemia and aid in
detecting IHD in at-risk women [46]. In one small study,
MRI was used to identify subendocardial ischemia in a
cohort of women with symptoms but no evidence of
obstructive CAD [46]. In a recent study of 204 women
with suspected or known CAD who underwent conven-
tional coronary angiography and dobutamine stress mag-
netic resonance, the sensitivity and specificity of MRI for
detecting obstructive CAD in women was found to be 85%
and 86%, respectively [47].
Prognostic data withMRI are limited. However, ina recent
study of a cohort of 266 women followed up for a mean of
6.2 years, the identification of inducible wall-motion abnor-
malities with dobutamine stress CMR predicted cardiac death
and MI [48]. Although additional sex-specific studies are
needed, CMR is emerging as a clinically useful modality in
the diagnostic and prognostic evaluation of women with
suspected IHD. The absence of ionizing radiation in CMR
may be an attractive technique for serial monitoring of
women with known CAD.
Recommendations
For women with symptoms and risk factors for CAD,
clinicians should first look at risk factors, symptoms, and the
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assessment should be followed by an estimation of functional
capacity because this is strongly linked to prognosis and is
useful in determining the appropriate noninvasive stress
testing modality. Current evidence supports the use of the
exercise ECG stress test as the initial test for the symptomatic
woman with a normal resting ECG and good exercise
tolerance (capable of >5 METs). The addition of nonexercise
parameters, calculation of functional capacity, and clinical
scores such as the Duke treadmill score to ST-segment
depressions improves the ability for diagnosis and evaluation
of prognosis in women [6, 7].
Cardiac imaging using contemporary SPECT MPI/stress
echocardiography techniques provides excellent diagnostic
accuracy and risk stratification in symptomatic women with
known or suspected IHD. Stress MPI/stress echocardiogra-
phy provides incremental value over clinical variables and
the exercise ECG in women with suspected or known
CAD. Local expertise should guide test selection. Of note,
SPECT MPI provides validated quantitative data on the
location, extent, and severity of stress-induced ischemia,
whereas the interpretation of stress echocardiography is
dependent on expertise and visual analysis. As per the
recent American Heart Association consensus statement,
symptomatic women with questionable exercise capacity,
those with an abnormal baseline ECG, and those with
diabetes mellitus, cardiac imaging with exercise or phar-
macologic stress should be the first test of choice. Evolving
evidence supports the use of cardiac CTA for the
noninvasive evaluation of the coronary arteries in the
setting of an abnormal or equivocal stress cardiac imaging
study. CMR can be useful in evaluating symptomatic
women with no evidence of obstructive CAD to evaluate
the coronary microvasculature for evidence of subendocar-
dial ischemia or abnormal coronary reserve. Figure 1
proposes a diagnostic pathway based on recent evidence
for evaluating symptomatic women at risk for IHD.
Conclusions
Contemporary techniques for cardiac imaging with stress
SPECT MPI and stress echocardiography are effective in
the diagnosis and risk stratification of symptomatic women
at risk for CAD. Insights from recent clinical trials have
provided evidence that the etiology of IHD in women is
multifactorial and includes obstructive CAD and dysfunc-
tion of the coronary microvasculature and endothelium.
Fig. 1 Proposed algorithm for evaluating symptomatic women at
intermediate risk for ischemic heart disease. Based on the recent
evidence, an assessment of functional capacity (an important predictor
of cardiac events in women) using the Duke Activity Status Index
(DASI) is included in this algorithm to assist in the selection of the
appropriate stress test. CTA—computed tomographic angiography;
ECG—electrocardiogram; Echo—echocardiography; EF—ejection
fraction; ETT—exercise treadmill test; Ex—exercise; LV—left ven-
tricular; METs—metabolic equivalents; MPI—myocardial perfusion
imaging; Rx—treatment. (Adapted from Shaw et al. [6] and Mieres et
al. [7].)
152 Curr Cardiol Rep (2010) 12:147–154Future imaging protocols that focus on measuring endothe-
lial function and detecting subclinical atherosclerosis will
be integrated into diagnostic and prognostic algorithms for
at-risk women. Emerging technology and protocols using
CMR, measurement of carotid intima-media thickness, and
brachial artery flow–mediated dilatation will be useful in
identifying endothelial dysfunction, microvascular disease,
or abnormal coronary reactivity in symptomatic women
with or without a normal stress echocardiography/SPECT
MPI in the setting of nonobstructive CAD. Identification of
these women is essential for the targeted prevention
strategies because they are at intermediate risk for cardiac
death and MI [10••].
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